Chinese cell therapy developer JW Therapeutics has raised HK$2.325 billion (nearly $300 million) in an initial public offering (IPO) in Hong Kong, on Tuesday, to finance the firm’s efforts to obtain China’s first CAR-T product approval.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
